Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

被引:0
作者
Bin Wu
Jinfang Shen
Huafeng Cheng
机构
[1] Renji Hospital,Department of Pharmacy Clinical Outcomes and Economics Group
[2] affiliated with the School of Medicine,undefined
[3] Shanghai Jiaotong University,undefined
来源
BMC Health Services Research | / 12卷
关键词
Hepatitis B; Lamivudine resistance; Rescue therapy; Cost-effectiveness;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 266 条
[31]  
Leung NW(2009)Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B J Hepatol 51 640-897
[32]  
Ghany MG(2004)Cost of chronic hepatitis B infection in China J Clin Gastroenterol 38 S175-528
[33]  
Doo EC(2008)The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons Value Health 11 527-251
[34]  
Lee JM(2008)Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI) Value Health 11 886-272
[35]  
Park JY(2004)Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 518-S12
[36]  
Kim Do Y(2000)Development of WHO guidelines on generalized cost-effectiveness analysis Health Econ 9 235-283
[37]  
Nguyen T(2011)Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis Med Care 49 267-14
[38]  
Hong SP(2009)EASL Clinical Practice Guidelines J Hepatol 50 243-8
[39]  
Kim SO(2009)National Institutes of Health consensus development conference statement: management of hepatitis B Hepatology 49 S4-76
[40]  
Chon CY(2008)Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263-111